Crystal form of acp-196, preparation method therefor and pharmaceutical composition thereof
AssigneeSolipharma LLC
InventorsXiaohong SHENG, Xiaoxia SHENG, Tao ZHU
Life of this patent
Estimating the term…
Abstract
Crystalline forms of ACP-196, preparation methods, pharmaceutical compositions and uses thereof in the preparation of drugs for treatment and/or prevention of Bruton's tyrosine kinase (BTK)-mediated disorders such as autoimmune diseases or disorders, heteroimmune diseases or disorders, cancers including lymphoma and inflammatory diseases or disorders. As compared with the known solid form of ACP-196, the crystalline forms of the present invention have advantages in crystallinity.
Claims12
ACP-196 Form 1, with the chemical structure shown in the following formula (I),
- characterized in that, Form 1 is a dihydrate, and its the X-ray powder diffraction pattern of Form 1, expressed as 2θ angles, has the following characteristic peaks:
- 7.6±0.2°, 10.5±0.2°, 12.6±0.2°, 15.2±0.2°, 17.9±0.2° and 21.7±0.2°.
ACP-196 Form 2, with the chemical structure shown in the following formula (II),
- characterized in that, the X-ray powder diffraction pattern of ACP-196 Form 2, expressed as 2θ angles, has the following characteristic peaks:
- 7.4±0.2°, 10.3±0.2°, 12.4±0.2°, 12.7±0.2°, 17.8±0.2° and 21.9±0.2°.
Dependencies are inferred from the claim text.